Identification and integrated analysis of key differentially expressed circular RNAs in ER-positive subtype breast cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J. Clin. 67(1), 7–30 (2017).
  MedlineGoogle Scholar
• 2 Chen W, Zheng R, Baade PD et al. Cancer statistics in China, 2015. CA Cancer J. Clin. 66(2), 115–132 (2016).
  MedlineGoogle Scholar
• 3 Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490(7418), 61–70 (2012).
  MedlineGoogle Scholar
• 4 Hsu MT, Coca-Prados M. Electron microscopic evidence for the circular form of RNA in the cytoplasm of eukaryotic cells. Nature 280(5720), 339–340 (1979).
  Medline CASGoogle Scholar
• 5 Kristensen LS, Hansen TB, Venø MT, Kjems J. Circular RNAs in cancer: opportunities and challenges in the field. Oncogene 37(5), 555–565 (2018). • Describe the various functions of circular RNA (circRNA) in cancer.
  Medline CASGoogle Scholar
• 6 Meng S, Zhou H, Feng Z et al. CircRNA: functions and properties of a novel potential biomarker for cancer. Mol. Cancer 16(1), 94 (2017). • Describes several properties of circRNAs in eukaryotic cells.
  MedlineGoogle Scholar
• 7 Han D, Li J, Wang H et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology 66(4), 1151–1164 (2017).
  Medline CASGoogle Scholar
• 8 Weng W, Wei Q, Toden S et al. Circular RNA ciRS-7-A promising prognostic biomarker and a potential therapeutic target in colorectal cancer. Clin. Cancer Res. 23(14), 3918–3928 (2017).
  Medline CASGoogle Scholar
• 9 Du WW, Yang W, Liu E, Yang Z, Dhaliwal P, Yang BB. Foxo3 circular RNA retards cell cycle progression via forming ternary complexes with p21 and CDK2. Nucleic Acids Res. 44(6), 2846–2858 (2016). •• CircRNA binds to proteins to format a ternary complex.
  MedlineGoogle Scholar
• 10 Yang W, Du WW, Li X, Yee AJ, Yang BB. Foxo3 activity promoted by non-coding effects of circular RNA and Foxo3 pseudogene in the inhibition of tumor growth and angiogenesis. Oncogene 35(30), 3919–3931 (2016).
  Medline CASGoogle Scholar
• 11 Zheng Q, Bao C, Guo W et al. Circular RNA profiling reveals an abundant circHIPK3 that regulates cell growth by sponging multiple miRNAs. Nat. Commun. 7, 11215 (2016). •• CircRNA functions as miRNA sponges.
  Medline CASGoogle Scholar
• 12 He R, Liu P, Xie X et al. CircGFRA1 and GFRA1 act as ceRNAs in triple negative breast cancer by regulating miR-34a. J. Exp. Clin. Cancer Res. 36(1), 145 (2017).
  MedlineGoogle Scholar
• 13 Liang HF, Zhang XZ, Liu BG, Jia GT, Li WL. Circular RNA circ-ABCB10 promotes breast cancer proliferation and progression through sponging miR-1271. Am. J. Cancer Res. 7(7), 1566–1576 (2017).
  Medline CASGoogle Scholar
• 14 Wang H, Xiao Y, Wu L, Ma D. Comprehensive circular RNA profiling reveals the regulatory role of the circRNA-000911/miR-449a pathway in breast carcinogenesis. Int. J. Oncol. 52(3), 743–754 (2018).
  Medline CASGoogle Scholar
• 15 Tang YY, Zhao P, Zou TN et al. Circular RNA hsa_circ_0001982 promotes breast cancer cell carcinogenesis through decreasing miR-143. DNA Cell Biol. 36(11), 901–908 (2017).
  Medline CASGoogle Scholar
• 16 Peng J, Zhang L, Yuan C et al. Expression profile analysis of long noncoding RNA in ER-positive subtype breast cancer using microarray technique and bioinformatics. Cancer Manag. Res. 9, 891–901 (2017).
  Medline CASGoogle Scholar
• 17 Kozomara A, Griffiths-Jones S. MiRBase: annotating high confidence microRNAs using deep sequencing data. Nucleic Acids Res. 42(D1), D68–D73 (2013).
  MedlineGoogle Scholar
• 18 Agarwal V, Bell GW, Nam J-W, Bartel DP. Predicting effective microRNA target sites in mammalian mRNAs. Elife 4, e05005 (2015).
  MedlineGoogle Scholar
• 19 Chang TH, Huang HY, Hsu JB-K, Weng SL, Horng JT, Huang HD. An enhanced computational platform for investigating the roles of regulatory RNA and for identifying functional RNA motifs. BMC Bioinformatics 14(Suppl. 2), S4 (2013).
  Medline CASGoogle Scholar
• 20 Chou CH, Shrestha S, Yang CD et al. MiRTarBase update 2018: a resource for experimentally validated microRNA-target interactions. Nucleic Acids Res. 46(D1), D296–D302 (2018).
  Medline CASGoogle Scholar
• 21 Yuan C, Zhu X, Han Y et al. Elevated HOXA1 expression correlates with accelerated tumor cell proliferation and poor prognosis in gastric cancer partly via cyclin D1. J. Exp. Clin. Cancer Res. 35(1), 15 (2016).
  MedlineGoogle Scholar
• 22 Hansen TB, Jensen TI, Clausen BH et al. Natural RNA circles function as efficient microRNA sponges. Nature 495(7441), 384–388 (2013).
  Medline CASGoogle Scholar
• 23 Finch PW, He X, Kelley MJ et al. Purification and molecular cloning of a secreted, Frizzled-related antagonist of Wnt action. Proc. Natl Acad. Sci. USA 94(13), 6770–6775 (1997).
  Medline CASGoogle Scholar
• 24 Bafico A, Gazit A, Pramila T, Finch PW, Yaniv A, Aaronson SA. Interaction of Frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J. Biol. Chem. 274(23), 16180–16187 (1999).
  Medline CASGoogle Scholar
• 25 Hirata H, Ueno K, Nakajima K et al. Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells. Br. J. Cancer 108(10), 2070–2078 (2013).
  Medline CASGoogle Scholar
• 26 Hirata H, Hinoda Y, Shahryari V et al. Genistein downregulates onco-miR-1260b and upregulates sFRP1 and Smad4 via demethylation and histone modification in prostate cancer cells. Br. J. Cancer 110(6), 1645–1654 (2014).
  Medline CASGoogle Scholar
• 27 Lánczky A, Nagy Á, Bottai G et al. MiRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients. Breast Cancer Res. Treat. 160(3), 439–446 (2016).
  Medline CASGoogle Scholar
• 28 Coscujuela Tarrero L, Ferrero G, Miano V et al. Luminal breast cancer-specific circular RNAs uncovered by a novel tool for data analysis. Oncotarget 9(18), 14580–14596 (2018).
  MedlineGoogle Scholar
• 29 Li S, Teng S, Xu J et al. Microarray is an efficient tool for circRNA profiling. Brief. Bioinformatics 73(11), 3852 (2018).
  Google Scholar
• 30 Nair AA, Niu N, Tang X et al. Circular RNAs and their associations with breast cancer subtypes. Oncotarget 7(49), 80967–80979 (2016).
  MedlineGoogle Scholar
• 31 Chen B, Wei W, Huang X et al. CircEPSTI1 as a prognostic marker and mediator of triple-negative breast cancer progression. Theranostics 8(14), 4003–4015 (2018).
  Medline CASGoogle Scholar
• 32 Zhou J, Zhang WW, Peng F, Sun JY, He ZY, Wu SG. Downregulation of hsa_circ_0011946 suppresses the migration and invasion of the breast cancer cell line MCF-7 by targeting RFC3. Cancer Manag. Res. 10, 535–544 (2018).
  Medline CASGoogle Scholar
• 33 Tsukamoto K, Ito N, Yoshimoto M et al. Allelic loss on chromosome 1p is associated with progression and lymph node metastasis of primary breast carcinoma. Cancer 82(2), 317–322 (1998).
  Medline CASGoogle Scholar
• 34 Ragnarsson G, Eiriksdottir G, Johannsdottir JT, Jonasson JG, Egilsson V, Ingvarsson S. Loss of heterozygosity at chromosome 1p in different solid human tumours: association with survival. Br. J. Cancer 79(9–10), 1468–1474 (1999).
  Medline CASGoogle Scholar
• 35 Han W, Han MR, Kang JJ et al. Genomic alterations identified by array comparative genomic hybridization as prognostic markers in tamoxifen-treated estrogen receptor-positive breast cancer. BMC Cancer 6, 92 (2006).
  MedlineGoogle Scholar
• 36 Climent J, Perez-Losada J, Quigley DA et al. Deletion of the PER3 gene on chromosome 1p36 in recurrent ER-positive breast cancer. J. Clin. Oncol. 28(23), 3770–3778 (2010).
  Medline CASGoogle Scholar
• 37 Goh JY, Feng M, Wang W et al. Chromosome 1q21.3 amplification is a trackable biomarker and actionable target for breast cancer recurrence. Nat. Med. 100, 3983–3918 (2017).
  Google Scholar
• 38 Cai Q, Zhang B, Sung H et al. Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. Nat. Genet. 46(8), 886–890 (2014).
  Medline CASGoogle Scholar
• 39 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 144(5), 646–674 (2011).
  Medline CASGoogle Scholar
• 40 Xu L, Xu X, Huang H et al. MiR-1260b promotes the migration and invasion in non-small cell lung cancer via targeting PTPRK. Pathol. Res. Pract. 214(5), 776–783 (2018).
  Medline CASGoogle Scholar
• 41 Li X, Song H, Liu Z, Bi Y. MiR-1260b promotes cell migration and invasion of hepatocellular carcinoma by targeting the regulator of G-protein signaling 22. Biotechnol. Lett. 40(1), 57–62 (2018).
  Medline CASGoogle Scholar
• 42 Liu DR, Guan QL, Gao MT, Jiang L, Kang HX. MiR-1260b is a potential prognostic biomarker in colorectal cancer. Med. Sci. Monit. 22, 2417–2423 (2016).
  Medline CASGoogle Scholar
• 43 Xu L, Li L, Li J et al. Overexpression of miR-1260b in non-small cell lung cancer is associated with lymph node metastasis. Aging Dis. 6(6), 478–485 (2015).
  MedlineGoogle Scholar
• 44 Shulewitz M, Soloviev I, Wu T, Koeppen H, Polakis P, Sakanaka C. Repressor roles for TCF-4 and Sfrp1 in Wnt signaling in breast cancer. Oncogene 25(31), 4361–4369 (2006).
  Medline CASGoogle Scholar
• 45 Kong L-Y, Xue M, Zhang Q-C, Su C-F. In vivo and in vitro effects of microRNA-27a on proliferation, migration and invasion of breast cancer cells through targeting of SFRP1 gene via Wnt/β-catenin signaling pathway. Oncotarget 8(9), 15507–15519 (2017).
  MedlineGoogle Scholar
• 46 Klopocki E, Kristiansen G, Wild PJ et al. Loss of SFRP1 is associated with breast cancer progression and poor prognosis in early stage tumors. Int. J. Oncol. 25(3), 641–649 (2004).
  Medline CASGoogle Scholar